Welcome to our dedicated page for Aldeyra Therapeu news (Ticker: ALDX), a resource for investors and traders seeking the latest updates and insights on Aldeyra Therapeu stock.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) is a clinical-stage biotechnology company focused on therapies for immune-mediated and metabolic diseases, with a particular emphasis on ophthalmology and rare retinal conditions. News about Aldeyra often centers on the progress of its RASP (reactive aldehyde species) modulator platform and its late-stage product candidates reproxalap and ADX-2191.
Investors following ALDX news can expect regular updates on regulatory milestones, such as the U.S. Food and Drug Administration’s review of the New Drug Application for topical ocular reproxalap in dry eye disease, extensions of Prescription Drug User Fee Act (PDUFA) target action dates, and feedback on proposed labeling. Aldeyra also reports on orphan drug and fast track designations from the FDA and the European Medicines Agency for ADX-2191 in primary vitreoretinal lymphoma, retinitis pigmentosa, and related inherited retinal dystrophies.
The company’s news flow includes clinical trial readouts and pipeline updates, such as Phase 2 data for ADX-629 in alcohol-associated hepatitis, preclinical results for ADX-248 in models of central nervous system diseases associated with inflammation, and decisions to prioritize next-generation RASP modulators ADX-248 and ADX-246. Aldeyra also issues releases about Special Protocol Assessment agreements, manufacturing inspections and outcomes, and participation in healthcare and ophthalmology conferences and research and development webcasts.
This ALDX news page aggregates these company communications so readers can track developments in Aldeyra’s RASP platform, ophthalmic programs, and broader immune-mediated disease pipeline over time. For investors and observers, the news stream provides context on clinical progress, regulatory interactions, and strategic pipeline decisions that shape the company’s future prospects.
Aldeyra Therapeutics (Nasdaq: ALDX) will host an Investor Roundtable Q&A via webcast on Thursday, June 20, 2024, at 8:00 a.m. ET.
This event will feature remarks from Todd C. Brady, M.D., Ph.D., President and CEO, followed by a Q&A session. Shareholders and prospective investors can submit questions via the webcast portal during the event or ahead of time by email starting Monday, June 17.
The live audio webcast and slide presentation will be accessible on the Aldeyra website, with a replay available for 90 days.
Aldeyra Therapeutics (Nasdaq: ALDX), a clinical-stage biotech firm focused on immune-mediated and metabolic diseases, announced that CEO Todd C. Brady will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event, featuring a discussion with Jefferies' SVP Kelly Shi, is scheduled for 3:30 p.m. ET on June 5, 2024. The company specializes in developing RASP modulators like reproxalap and ADX-2191 for treating conditions such as dry eye disease and retinitis pigmentosa. Webcast details are available on Aldeyra's website, with the session archived for 90 days.
Aldeyra Therapeutics has enrolled the first patient in a Phase 3 clinical trial for reproxalap in treating dry eye disease, aiming for a potential NDA resubmission by the second half of 2024. The company expects positive results to lead to an NDA resubmission to the FDA, incorporating acute and chronic improvements in symptoms and ocular redness. The planned review period for the resubmission is six months, with promising preliminary data from previous trials.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Aldeyra Therapeu (ALDX)?
What is the market cap of Aldeyra Therapeu (ALDX)?
